A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma - Report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group

Brazilian Journal of Medical and Biological Research

Volumn 37, Issue 5, 2004, Pages 719-728

  Santini, Gino ^a   De Souza, C ^b   Aversa, S ^c   Patti, C ^d   Tedeschi, L ^e   Candela, M ^f   Olivieri, A ^f   Chisesi, T ^g   Rubagotti, A ^a   Centurioni, R ^h   Nardi, V ^a   Congiu, M ^a   Gennaro, M ^a   Truini, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^d VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^e SAN CARLO BORROMEO HOSPITAL   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g Headache Centre   (Italy)

^h Civitanova Marche Hospital   (Italy)

Author keywords

Localized aggressive non Hodgkin's lymphoma; Radiotherapy; Toxicity; VACOP B

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADJUVANT THERAPY; ADULT; AGE; ALOPECIA; ANEMIA; ARTICLE; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; GENDER; GRANULOCYTOPENIA; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; ITALY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OPEN STUDY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PROBABILITY; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; SURVIVAL RATE; SURVIVAL TIME; TIME; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 2542522472     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2004000500014     Document Type: Article

References (28)

1. Sutcliffe SB, Gospodarowicz MK, Bush RS, Brown TC, Chua T, Bean HA, Clark RM, Dembo A, Fitzpatrick PJ & Peters MV (1985). Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiotherapy and Oncology, 4: 211-223.
2. Nissen NI, Ersboll J, Hansen HS, Walbom-Jorgensen S, Pedersen-Bjergaard J, Hansen MM & Rygard J (1983). A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer, 52: 1-7.
3. Ruijs CD, Dekker AW, van Kempen-Harteveld ML, van Baarlen J & Hordijk GJ (1994). Treatment of localized non-Hodgkin's lymphomas of the head and neck. Cancer, 74: 703-707.
4. Kimby E, Brandt L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care (2001). A systematic overview of chemotherapy effects in aggressive non-Hodgkin's lymphoma. Acta Oncologica, 40: 198-212.
5. Miller TP & Jones SEM (1980). Is there a role for radiotherapy in localized diffuse lymphomas? Cancer Chemotherapy and Pharmacology, 4: 67-70.
6. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman Jr CA & Miller TP (1993). Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New England Journal of Medicine, 328: 1002-1006.
7. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E & Fisher RI (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. New England Journal of Medicine, 339: 21-26.
8. Cosset JM (1998). Chemoradiotherapy for localized non-Hodgkin's lymphoma (Editorial). New England Journal of Medicine, 339: 44-45.
9. Munck JN, Dhermain F, Koscielny S, Girinsky T, Carde P, Bosq J, Decaudin D, Julieron M, Cosset JM & Hayat M (1996). Alternating chemotherapy and radiotherapy for limited-stage intermediate and high-grade non Hodgkin's lymphomas: long-term results for 96 patients with tumors >5 cm. Annals of Oncology, 7: 925-931.
10. Shenkier TN, Voss N, Fairey R, Gascoyne RD, Hoskins P, Klasa R, Klimo P, O'Reilly SEM, Sutcliffe S & Connors JM (2002). Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency. Journal of Clinical Oncology, 20: 197-204.
11. Gordon LI, Harrington D, Andersen J et al. (1992). Comparison of second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. New England Journal of Medicine, 327: 1342-1349.
12. Sertoli MR, Santini G, Chisesi T et al. (1994). MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphomas: Results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. Journal of Clinical Oncology, 12: 1366-1374.
13. Freilone R, Botto B, Vitolo U et al. (1996). Combined modality treatment with a weekly brief chemotherapy (ACOP-B) followed by locoregional radiotherapy in localized-stage intermediate- to high-grade non-Hodgkin's lymphoma. Annals of Oncology, 7: 919-924.
14. Zinzani PL, Stefoni V, Tani M et al. (2001). MACOP-B regimen followed by involved-field radiation therapy in early-stage aggressive non-Hodgkin's lymphoma patients: 14-year update results. Leukemia and Lymphoma, 42: 989-995.
15. O'Reilly SEM, Hoskins P, Klimo P & Connors JM (1991). MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. Annals of Oncology, 2 (Suppl 1): 17-23.
16. Santini G, Salvagno L, Leoni P et al. (1998). VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the Non-Hodgkin's Lymphoma Cooperative Study Group. Journal of Clinical Oncology, 16: 2796-2802.
17. National Cancer Institute Sponsored Study of Classifications of Non-Hodgkin's Lymphomas (1982). Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer, 49: 2112-2135.
18. Carbone PP, Kaplan HS, Musshoff K, Smithers DW & Tubiana M (1971). Report of the Committee of Hodgkin's Disease Staging Classification. Cancer Research, 31: 1860-1861.
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET & Carbone PP (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology, 5: 649-655.
20. Chisesi T, Polistena P, Contu A et al. (2001). Cemp, a mitoxanthrone containing combination, in the treatment of intermediate and high grade non-Hodgkin's lymphoma: an effective and non toxic therapeutic alternative for adult and elderly patients. Leukemia and Lymphoma, 41: 125-136.
21. Santini G, De Souza C, Congiu AM et al. (1999). High-dose cyclophosphamide followed by autografting can improve the outcome of relapsed or resistant non-Hodgkin's lymphomas with involved or hypoplastic bone marrow. Leukemia and Lymphoma, 33: 321-330.
22. Cheson BD, Horning SJ, Coiffier B et al. (1999). Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. NCl sponsored International Study Group. Journal of Clinical Oncology, 17: 1244-1252.
23. Kaplan EL & Meier P (1958). Nonparametric estimation from incomplete observations. Journal of the American Statistical Association B, 53: 457-481.
24. Cox DR (1972). Regression models and life tables. Journal of the Royal Statistical Society, 34: 187-220.
25. Anonymous (1993). A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. New England Journal of Medicine, 329: 987-994.
26. Velasquez WS, Cabanillas F, Salvador P et al. (1988). Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood, 71: 117-122.
27. Coiffier B, Lepage E, Brière J et al. (2003). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346: 235-241.
28. Fisher RI & Shah P (2003). Current trends in large cell lymphoma. Leukemia, 17: 1948-1960.